CA-NETAPP
NetApp, a global cloud-led, data-centric software company, today announced the renewal of its partnership agreement with Ducati Corse for the 2023 to 2025 seasons and names NetApp the team’s Official Data Infrastructure Partner. The latest innovation resulting from this partnership is a virtual data management and insights solution for race analytics and R&D that uses NetApp ONTAP® with NetApp SnapMirror™ and NetApp FlexCache™.
The world of grand prix racing relies heavily on speed. When Ducati Corse found its synchronization times between the racetrack and between engineers across multiple locations, including the Borgo Panigale HQ, was too slow to be effective, they looked to NetApp to help design a new data insights and management solution. Delivering almost real-time data sharing and analytics, NetApp helps tech teams extract maximum value from test and race weekend sessions that can mean the difference between pole position and a starting position down the grid.
“Through our joint innovation with Ducati, we’ve played a pivotal role in revolutionizing their data infrastructure, enhancing every facet of their software development, design and engineering,” said Gabie Boko, Chief Marketing Officer at NetApp. “Our collaboration has enabled near real-time data sharing and analytics, accelerating the entire landscape of elite motorcycle racing data analysis. Ducati is one of the shining stars in Italy’s ‘Motor Valley,’ and we’re committed to riding along with Ducati to help them achieve greater success.”
The benefits of the co-engineered solution include:
- Seamless connection between Ducati’s data infrastructure clusters so engineers can access the same always-on data from anywhere.
- Data insights captured in an elite racing environment to be used across all Ducati business units.
- A software-defined approach to create a powerful but efficient data storage foundation built on NetApp ONTAP® – delivering the power of NetApp’s decades of enterprise data management innovation and product leadership.
- Optimized data transfer powered by NetApp ONTAP with SnapMirror for unified, high-speed, and secure replication of data.
- FlexCache remote caching for actively read data only. FlexCache improves the speed and productivity of collaboration across multiple locations, increases data throughput and reducing WAN bandwidth costs.
“With this data management platform, we can seamlessly manage, share, protect and move our data in our hybrid cloud environment from the factory to our garage, and to the track during a race, and share data with our engineers in a way that is fast, secure, and seamless,” said Gigi Dall’Igna, General Manager of Ducati Corse. “As Triple Crown holders and with our first MotoGP Riders’ World Title in 15 years, we need the best technology, data, and data management to ensure we defend these titles and we’re confident in our partnership with NetApp to help us do this.”
Since 2018, NetApp and Ducati have collaborated to help Ducati successfully manage 200 applications and support 90 virtual machines in a disaster recovery center. NetApp provides the speed and capacity to help Ducati manage branch operations and perform on-site data analysis while moving data to a hybrid cloud, reducing the time it took to develop prototypes and get new motorcycles to market.
About Ducati
Founded in 1926, since 1946 Ducati has been manufacturing sport-inspired motorcycles characterised by high-performance engines, innovative design, and cutting-edge technology. The Ducati factory is located in Bologna’s Borgo Panigale district. The model range covers several market segments with the following families: DesertX, Diavel, XDiavel, Hypermotard, Monster, Multistrada, Panigale, Streetfighter and SuperSport. In 2015, Ducati presented the Ducati Scrambler: a new brand made of bikes, accessories and apparel that stands out for its creativity and self-expression. In 2020, Ducati unveiled the Multistrada V4, the world's first motorcycle equipped with front and rear radar, which with its technology marks a new milestone for the world of two wheels. Ducati’s iconic motorcycles, together with an extensive range of bike accessories and technical and lifestyle apparel, are distributed in 90 countries worldwide. In 2022, Ducati delivered 61,562 bikes to passionate clients. Ducati competes with official teams in the MotoGP World Championship and Superbike World Championship. In MotoGP, where the Company has been racing since 2003, Ducati won the Constructors' title in 2007, 2020, 2021 and 2022, the Teams' title in 2007, 2021 and 2022 and the Rider’s title in 2007 and 2022, becoming two times World Champion. In Superbike, Ducati has won 18 Constructors' titles and 15 Riders' titles, confirming its position as the most successful manufacturer in the category. 2022 marked an unprecedented year for Ducati: for the first time in its history, the Company won the Triple Crown in both the MotoGP and Superbike World Championships. From 2023 until 2026, the motorcycle manufacturer is the sole official supplier of motorbikes for the FIM Enel MotoE™ World Cup, the electric class of the MotoGP World Championship.
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
Additional Resources
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231012293667/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom